Nice's decision to withhold a breakthrough prostate cancer drug is a "cruel twist" as it comes "just days" after a study confirmed its success, campaigners have said.
Prostate Cancer UK called on Nice, who vet the cost effectiveness of medicine for NHS patients, to change its "post-chemo" policy on new drugs.
Enzalutamide is already licensed for those who've had chemotherapy but this trial will hopefully establish a robust base of evidence to demonstrate that it should be available beforehand.
This is good news but sadly won't help the one man an hour who dies of prostate cancer at present.
We need to see drugs like enzalutamide available sooner rather than later, and so it's a cruel twist that this study comes just days after Nice ruled out the drug for men who have already had chemotherapy and the only other drug available at this stage, abiraterone.
More top news
Another Briton named as Jason Robert Parnell is missing after the accident near the popular Koh Samui island resort.
The text-to-register service allows mobile users to add their number to the Telephone Preference Service 'do not call' database.
A consumer report found that a number of once-a-day sunscreens decreased in protection by an average of 74% after six to eight hours.